Surufatinib (trade name Sulanda) is pharmaceutical drug for the treatment of cancer.

In China, it is approved for late-stage, well-differentiated, extrapancreatic neuroendocrine tumors.

[1] It is also under investigation for the treatment of other types of solid tumors.

[2][3] Surufatinib targets fibroblast growth factor receptor 1 (FGFR1).

This antineoplastic or immunomodulatory drug article is a stub.